BIIB091   Click here for help

GtoPdb Ligand ID: 11791

Synonyms: BIIB-091 | compound 51 [PMID: 34734694]
PDB Ligand
Compound class: Synthetic organic
Comment: BIIB091 was disclosed as an orthosteric, ATP-competitive inhibitor of the Tec family kinase, Bruton's tyrosine kinase (BTK) [1]. It is being investigated by Biogen to block the inflammatory processes that drive neurodegeneration in multiple sclerosis. The molecule with no specified stereo centres is represented by compound 71 [WO2018191577A1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 127.91
Molecular weight 542.29
XLogP 2.6
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Cn1ncc(c1)Nc1nccc(n1)c1ccc2c(c1)CN(CC[C@H]2NC(=O)c1nnn(c1)C(C)(C)C)C1COC1
Isomeric SMILES O=C(c1cn(C(C)(C)C)nn1)N[C@H]1c2ccc(c3ccnc(Nc4cn(C)nc4)n3)cc2CN(C2COC2)CC1
InChI InChI=1S/C28H34N10O2/c1-28(2,3)38-15-25(34-35-38)26(39)32-24-8-10-37(21-16-40-17-21)13-19-11-18(5-6-22(19)24)23-7-9-29-27(33-23)31-20-12-30-36(4)14-20/h5-7,9,11-12,14-15,21,24H,8,10,13,16-17H2,1-4H3,(H,32,39)(H,29,31,33)/t24-/m1/s1
InChI Key JSAQBOQCZJHWMA-XMMPIXPASA-N
No information available.
Summary of Clinical Use Click here for help
BIIB091 has been advanced to preliminary clinical evaluations in healthy volunteers.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04564612 Study of BIIB091 Modified Release Formulations in Healthy Participants Phase 1 Interventional Biogen
NCT03943056 A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants Phase 1 Interventional Biogen